Showing 1231-1240 of 1583 results for "".
- Octane Aesthetics Tech Forum Panelists React to FDA Approval of Oral Semaglutidehttps://modernaesthetics.com/news/octane-aesthetics-tech-forum-panelists-react-to-fda-approval-of-oral-semaglutide/2485572/At the 2026 Octane Aesthetics Tech Forum, panelists weighed in on the recent FDA approval of oral semaglutide, offering a mix of cautious optimism and clinical realism. While the approval marks a milestone in expanding GLP-1 receptor agonist (RA) access, most experts on the panel said oral versio
- Octane Aesthetics Tech Forum: Clinical Strategies for Managing Rapid Weight Loss in Aestheticshttps://modernaesthetics.com/news/octane-aesthetics-tech-forum-clinical-strategies-for-managing-rapid-weight-loss-in-aesthetics/2485537/The widespread use of GLP-1 receptor agonists (GLP-1 RAs) is ushering in a new era of aesthetic medicine that demands a more nuanced approach to skin aging, hormonal health, and treatment planning. That was the consensus from a panel of aesthetic surgeons and regenerative medicine experts
- Injectable Skin Boosters Market Set to Exceed $3.2 Billion by 2032, Driven by HA-Based Rejuvenation Trendshttps://modernaesthetics.com/news/injectable-skin-boosters-market-set-to-exceed-32-billion-by-2032-driven-by-ha-based-rejuvenation-trends/2485495/The global market for injectable skin boosters is projected to more than double over the next decade, climbing from $1,492.17 million in 2025 to an estimated $3,263.80 million by 2032, according to new data from MMR Statistics. This represents a compound annual gro
- AAFPRS President Outlines “Three Rs” of Facial Plastic Surgeryhttps://modernaesthetics.com/news/aafprs-president-outlines-three-rs-of-facial-plastic-surgery/2485394/As patient interest in facial aesthetic and reconstructive procedures continues to grow, the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) is emphasizing the importance of specialty training through a new public education framework: the “Three Rs of the AAFPRS:” rhinoplas
- FDA Approves Once-Daily Oral Semaglutidehttps://modernaesthetics.com/news/fda-approves-once-daily-oral-semaglutide/2485258/The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-daily oral formulation of semaglutide, marketed as Wegovy® pill, marking the first oral GLP-1 receptor agonist approved for chronic weight management in the United States. The approval includes indications for adults with
- Lumenis Debuts Stellar M22™ with XPL™ at ASDS 2025, Showcases Single-Session Clearance Datahttps://modernaesthetics.com/news/lumenis-debuts-stellar-m22-with-xpl-at-asds-2025-showcases-single-session-clearance-data/2484554/Lumenis Be. Ltd. introduced the next-generation Stellar M22™ with XPL™ Technology during the 2025 Annual American Society for Dermatologic Surgery (ASDS) Meeting, highlighting single-session clearance rates of up to 100% for vascular and pigmented lesions. The multi-application aesthetic platform
- Skin of Color Society Media Day Analyzes Latest Trendshttps://modernaesthetics.com/news/skin-of-color-society-media-day-analyzes-latest-trends/2484533/In an era of misinformation and viral skincare fads, the Skin of Color Society’s (SOCS) 8th Annual Media Day offered a timely and authoritative voice, gathering top board-certified dermatologists to address critical dermatologic topics relevant to patients with skin of color. From trending TikTok
- PlasmaGLO HALO Mask Expands LED Therapy to Face, Neck, and Scalphttps://modernaesthetics.com/news/plasmaglo-halo-mask-expands-led-therapy-to-face-neck-and-scalp/2484403/Rajani MD has announced the release of the PlasmaGLO HALO Mask, a second-generation at-home LED light therapy device intended to treat signs of aging across the face, neck, and scalp. The new device builds on the brand’s original PlasmaGLO LED Mask by expanding treatment zones to include the hair
- FDA Approves Restylane Lyft for Chin Augmentation in Adultshttps://modernaesthetics.com/news/fda-approves-restylane-lyft-for-chin-augmentation-in-adults/2484326/Galderma announced today that the U.S. Food and Drug Administration (FDA) has approved Restylane® Lyft™ with Lidocaine for chin augmentation in adults over 21 with mild-to-moderate chin retrusion.
- Facial Aesthetic Surgical Training May Lag Behind Market Demand, Study Findshttps://modernaesthetics.com/news/facial-aesthetic-surgical-training-may-lag-behind-market-demand-study-finds/2484290/A new analysis published in the Journal of Plastic, Reconstructive & Aesthetic Surgery suggests that US plastic surgery residency programs may not be fully aligned with procedural trends in the growing facial aesthetics market. The study compares Accreditation Council for Graduate Me